

RECEIVED  
CENTRAL FAX CENTER



**GENAISSANCE  
PHARMACEUTICALS**

SEP 21 2004

FIVE SCIENCE PARK  
NEW HAVEN, CT 06511  
TEL. 203.773.1450  
FAX. 203.562.9377  
WWW.GENAISSANCE.COM

---

To: Commissioner for Patents

Fax Number: 703.872.9306

Date: September 21, 2004

From: Eileen McCaughern

Company: U.S. Patent & Trademark Office

Subject: U.S. Appl. No. 09/811,285

Pages: 6 (including cover sheet)

---

Please see attached.

---

The document(s) accompanying this facsimile may contain information from Genaisance Pharmaceuticals that is confidential, proprietary, and/or legally privileged. The information is intended only for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or the taking of any action in reliance on the contents of this faxed information is strictly prohibited, and the document(s) should be returned to this company immediately. If you have received this fax in error, please notify us by telephone immediately, so that Genaisance may arrange for the return of the original document(s) at no cost to you.

RECEIVED  
CENTRAL FAX CENTER

Docket No. MWH-0303US2

SEP 21 2004

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: **Connie M. Drysdale et al.**  
Application No.: **09/811,285**  
Filed: **March 16, 2001 (continuation of PCT/US00/10125, filed April 13, 2000)**  
Confirmation No.: **2691**  
Group No.: **1646**  
Examiner: **Murphy, J.F.**  
For: **ASSOCIATION OF  $\beta_2$ -ADRENERGIC RECEPTOR  
HAPLOTYPES WITH DRUG RESPONSE**

Commissioner for Patents

Certificate of Facsimile Transmission

I hereby certify under 37 C.F.R. § 1.8 that this correspondence is being transmitted by facsimile to the United States Patent and Trademark Office, Commissioner for Patents, TC 1600, at (703) 872-9306, on 9/21/04.

  
Eileen McCaughyRESPONSE TO RESTRICTION REQUIREMENT

In response to the Office Action dated August 24, 2004 regarding the above-captioned application, please amend the application as follows:

**Amendments to the Claims begin on page 2 of this paper.**

**Remarks begin on page 3 of this paper.**